OBSN — Obseva SA Share News
0.000.00%
Last trade - 00:00- CH₣0.14m
- -CH₣2.20m
- $19.64m
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary
Brief: Ernest Loumaye Reports 9.37% Stake In Obseva SA As Of Feb 28, 2023 - SEC Filing
Brief: ObsEva Announces Delisting Of OBSV From The Nasdaq Stock Market Effective March 23
Brief: ObsEva Announces Update Towards Its Reorganization To Consolidate Operations In Switzerland
Brief: Obseva Announces Brian O'Callaghan Stepped Down As Chief Executive Officer Effective February 23, 2023
Brief: Obseva SA To Begin Filing Periodic Reports, Registration Statements
Brief: ObsEva Announces Dismissal Of Moratorium Proceedings
Brief: Obseva Evidences Compliance With Nasdaq’S Stockholder’S Equity Rule And Announces Moratorium Dismissal Request Filing
Swiss stocks - Factors to watch on December 14
Brief: Obseva SA Files For Mixed Shelf Of Up To $100 Mln
Brief: Obseva SA Board Approves An Increase Of Its Share Capital
Brief: Obseva Announces Third Quarter 2022 Financial Results
ObsEva surges on license sale of preterm labor drug to XOMA Corp
Swiss stocks - Factors to watch on November 22
Swiss stocks - Factors to watch on November 7th
Brief: Obseva SA-Entered Into An Amendment & Forbearance Extension Agreement With Jgb Management, Related To Amended & Restated Securities Purchase Agreement